325 related articles for article (PubMed ID: 27030586)
1. Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen.
Alves RPDS; Pereira LR; Fabris DLN; Salvador FS; Santos RA; Zanotto PMA; Romano CM; Amorim JH; Ferreira LCS
Clin Vaccine Immunol; 2016 Jun; 23(6):460-469. PubMed ID: 27030586
[TBL] [Abstract][Full Text] [Related]
2. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
3. Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design.
Ramírez R; Falcón R; Izquierdo A; García A; Alvarez M; Pérez AB; Soto Y; Muné M; da Silva EM; Ortega O; Mohana-Borges R; Guzmán MG
Virus Genes; 2014 Oct; 49(2):185-95. PubMed ID: 24854144
[TBL] [Abstract][Full Text] [Related]
4. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.
Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E
J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant.
Amorim JH; Diniz MO; Cariri FA; Rodrigues JF; Bizerra RS; Gonçalves AJ; de Barcelos Alves AM; de Souza Ferreira LC
Vaccine; 2012 Jan; 30(5):837-45. PubMed ID: 22178517
[TBL] [Abstract][Full Text] [Related]
6. NS5 from Dengue Virus Serotype 2 Can Adopt a Conformation Analogous to That of Its Zika Virus and Japanese Encephalitis Virus Homologues.
El Sahili A; Soh TS; Schiltz J; Gharbi-Ayachi A; Seh CC; Shi PY; Lim SP; Lescar J
J Virol; 2019 Dec; 94(1):. PubMed ID: 31597763
[TBL] [Abstract][Full Text] [Related]
7. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice.
Lu H; Xu XF; Gao N; Fan DY; Wang J; An J
Mol Immunol; 2013 Jun; 54(2):109-14. PubMed ID: 23270684
[TBL] [Abstract][Full Text] [Related]
9. T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification.
Pinto PBA; Assis ML; Vallochi AL; Pacheco AR; Lima LM; Quaresma KRL; Pereira BAS; Costa SM; Alves AMB
Front Immunol; 2019; 10():1522. PubMed ID: 31333657
[TBL] [Abstract][Full Text] [Related]
10. [Research progress in the structure and function of dengue virus non-structural 1 protein].
Chen Y; Ren RW; Liu JW
Bing Du Xue Bao; 2014 Nov; 30(6):683-8. PubMed ID: 25868284
[TBL] [Abstract][Full Text] [Related]
11. Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.
Lim HX; Lim J; Poh CL
Med Microbiol Immunol; 2021 Feb; 210(1):1-11. PubMed ID: 33515283
[TBL] [Abstract][Full Text] [Related]
12. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.
Weiskopf D; Angelo MA; Sidney J; Peters B; Shresta S; Sette A
J Virol; 2014 Oct; 88(19):11383-94. PubMed ID: 25056881
[TBL] [Abstract][Full Text] [Related]
13. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
14. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
Front Immunol; 2019; 10():59. PubMed ID: 30761131
[TBL] [Abstract][Full Text] [Related]
15. Recombinant DENV 2 NS5: An effective antigen for diagnosis of DENV infection.
Zhang T; Wang ML; Zhang GR; Liu W; Xiao XQ; Yang YS; Li JT; Xun ZM; Li DY; Chan PKS
J Virol Methods; 2019 Mar; 265():35-41. PubMed ID: 30562608
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes.
Gao G; Wang Q; Dai Z; Calcedo R; Sun X; Li G; Wilson JM
Hum Gene Ther; 2008 Sep; 19(9):927-36. PubMed ID: 18788905
[TBL] [Abstract][Full Text] [Related]
17. Identification and molecular characterization of human antibody fragments specific for dengue NS5 protein.
Zhao Y; Moreland NJ; Tay MY; Lee CC; Swaminathan K; Vasudevan SG
Virus Res; 2014 Jan; 179():225-30. PubMed ID: 24262074
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
[TBL] [Abstract][Full Text] [Related]
19. Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge.
Henriques HR; Rampazo EV; Gonçalves AJ; Vicentin EC; Amorim JH; Panatieri RH; Amorim KN; Yamamoto MM; Ferreira LC; Alves AM; Boscardin SB
PLoS Negl Trop Dis; 2013; 7(7):e2330. PubMed ID: 23875054
[TBL] [Abstract][Full Text] [Related]
20. Combination of Modified NS1 and NS3 as a Novel Vaccine Strategy against Dengue Virus Infection.
Kao YS; Yu CY; Huang HJ; Tien SM; Wang WY; Yang M; Anderson R; Yeh TM; Lin YS; Wan SW
J Immunol; 2019 Oct; 203(7):1909-1917. PubMed ID: 31451673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
